<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437670</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 2011-0585</org_study_id>
    <nct_id>NCT01437670</nct_id>
  </id_info>
  <brief_title>Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin</brief_title>
  <acronym>OAB</acronym>
  <official_title>A Prospective, Multicenter, Observation Study to Estimate the Dry Mouth in OAB Patients With Solifenacin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheil General Hospital and Womenâ€™s Healthcare Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, observation study to estimate the dry mouth in OAB patients with
      solifenacin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To estimate the dry mouth and their impact on the efficacy of the drug in overactive bladder
      patients with solifenacin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of the total score in Xerostomia inventory XI from baseline</measure>
    <time_frame>after 8 weeks of treatment from baseline</time_frame>
    <description>11-item summated rating scale. Respondents were asked to choose one of five responses ('never', scoring 1~'very often', 5) total best and worst values: 11 and 49</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global response assessment</measure>
    <time_frame>after 8 weeks of treatment from baseline</time_frame>
    <description>range, 1~7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of the total score in overactive bladder symptom score (OABSS) from baseline</measure>
    <time_frame>after 8 weeks treatment from baseline</time_frame>
    <description>total best and worst values: 0 and 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) of dry mouth</measure>
    <time_frame>after 8 weeks treatment from baseline</time_frame>
    <description>The changes of the Visual Analog Scale (VAS) of dry mouth from baseline (range, 0~10)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">262</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>dry mouth patients with solifenacin</arm_group_label>
    <description>dry mouth patients with solifenacin 5mg, 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin 5mg, 10mg</intervention_name>
    <description>solifenacin 5mg, 10mg</description>
    <arm_group_label>dry mouth patients with solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with overactive bladder

          1. male or female patients with 20 years of age or older

          2. clinical history of OAB for at least 3 months prior to visit 2

          3. more than 3 in total score and 2 in Q 3 index from OABSS questionnaire
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) male or female patients with 20 years of age or older 2) clinical history of OAB
             for at least 3 months prior to visit 2 3) more than 3 in total score and 2 in Q 3
             index from OABSS questionnaire

        Exclusion Criteria:

          -  1) In clinical trial, female with pregnant, intent to become pregnant or
             breast-feeding 2)post-voided residual urine volume &gt; 150ml 3) a history of
             catheterization due to acute urinary retention 4) a history of pelvic surgery within 6
             months 5) 6) 7) a history of neurovascular disease such as Parkinson's disease,
             cerebral vascular disease, spinal injury or multiple sclerosis 8)patients with
             indwelling catheter or intermittent catheterization 9) active or recurrent (&gt;3
             episodes per year) urinary tract infection 10) the use of the following medication at
             least 2 weeks

          -  anticholinergics

          -  Tricyclic antidepressants,anti-epilepsy drug, anti-Parkinson's disease drug,
             anti-arrythmia drug type I

          -  Chlorpromazine, Thioridazine, Piperazine

          -  MAO inhibitor 11) Patient is currently taking or has taken within the past 4 weeks
             alpha-blocker for the treatment of benign prostatic hypertrophy 12) Patient is
             currently taking or has taken within the past 8 weeks 5ARI or estrogen medication 13)
             Patient is currently using or has used medications with known activities as inhibitors
             or inducers of cytochrome P4503A4 (CYP3A4)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoung-Soo Choo, M.D., pH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-222</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Soo Choo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

